Latest Breaking News On - Chezy barenholz - Page 4 : comparemela.com

Innocan Pharma Corporation: Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following

Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

Innocan Pharma Corporation: Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta (Newsfile

Innocan Pharma Corporation: Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel

Innocan Pharma Corporation: Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development

Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - July 12, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it